BioXcel (#BTAI) is a clinical-stage biotechnology company looking to commercialize neuroscience and oncology products developed with the help of their unique AI technology. I go through the data they have seen to date and upcoming catalysts that are likely to significantly affect the stock in the short term. As well, I touch on Cassava Sciences’ update on PTI-125 and an interesting coincidence regarding the structure of the molecule. Credit goes to twitter user: @NoseRubInvest for finding this! Finally, I touch on updates from $TRVN, $NVAX and $TGTX.
If you want to help the show, you can donate here: https://tips.pinecast.com/jar/breaking-biotech
You can also open an account at Tastyworks using my referral code: https://start.tastyworks.com/#/login?referralCode=ZWQ77XG2PZ
Follow me on twitter @matthewlepoire Send me an email firstname.lastname@example.org http://www.breakingbiotech.com #breakingbiotech
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech